October 2015October 2015
New Product - Xigduo XR
Xigduo XR (dapagliflozin/metformin hydrochloride) combines two antihyperglycaemic agents, dapagliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member of the biguanide class, with complementary mechanisms of action to improve both fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) in patients with type 2 diabetes. Xigduo XR is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. It is contraindicated in diabetic ketoacidosis, diabetic precoma; moderate or severe renal impairment (creatinine clearance < 60 mL/min or eGFR < 60 mL/min/1.732); acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock, or intravascular administration of iodinated contrast agents; acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, pulmonary embolism, recent myocardial infarction, shock, acute significant blood loss, sepsis, gangrene, pancreatitis; during or immediately following surgery where insulin is essential, elective major surgery; hepatic impairment; acute alcohol intoxication, alcoholism; and lactation. Xigduo XR 5/1000 containing dapagliflozin 5 mg/metformin hydrochloride 1000 mg is available in a pack of 56 extended release tablets, Xigduo XR 10/500 containing dapagliflozin 10 mg/metformin hydrochloride 500 mg is available in a pack of 28 extended release tablets, and Xigduo XR 10/1000 containing dapagliflozin 10 mg/metformin hydrochloride 1000 mg is available in a pack of 28 extended release tablets.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au